Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.43 |
| ▸ | WNT3A | P56704 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558072 | 0.81 | LMNA (0.45) | LMNAGAATP53SLC6A2SLC6A4 | |
| SCHEMBL4469871 | 0.80 | TSHR (0.50) | LMNAGAATP53SLC6A2SLC6A4 | |
| SCHEMBL15129453 | 0.78 | LMNA (0.55) | LMNAGAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16487401 | 0.74 | SMN1; SMN2 (0.58) | LMNAGAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5358195 | 0.74 | CTNNB1 (0.57) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL25214391 | 0.71 | LMNA (0.56) | LMNAGAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24201 | 0.71 | LMNA (0.60) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL5660835 | 0.71 | CTNNB1 (0.58) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL746794 | 0.70 | LMNA (0.64) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL28634751 | 0.70 | LMNA (0.64) | LMNAGAACTNNB1WNT3ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1830837-B1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY STEAROYL-COA DESATURASE ENZYMES | XENON PHARMACEUTICALS INC (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-7919496-B2 | 5-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]-[1,3,4]thiadiazole-2-carboxylic acid ethyl ester; metabolic disorders type II diabetes, impaired glucose tolerance, insulin resistance, obesity, fatty liver, non-alcoholic steatohepatitis, dyslipidemia and metabolic syndrome; cardiovascular disorders | XENON PHARMACEUTICALS INC. (CA) | 2011-04-05 | — | — | US | disclosed |
| EP-2289510-A1 | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes | Xenon Pharmaceuticals Inc. (CA) | 2011-03-02 | — | — | EP | disclosed |
| US-20080108629-A1 | Heterocyclic Derivatives for the Treatment of Diseases Mediated by Stearoyl-Coa Desaturase Enzymes | XENON PHARMACEUTICALS INC. (CA) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108629-A1 | Heterocyclic Derivatives for the Treatment of Diseases Mediated by Stearoyl-Coa Desaturase Enzymes | SCD, SCD5, ECHS1 | LMNA 646/4885GAA 413/4885TP53 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.